Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 3, 2007, Pages 161-167

  Fuwa, Nobukazu ^a,c   Kodaira, Takesi ^a   Tachibana, Hiroyuki ^a   Nakamura, Tatsuya ^a   Daimon, Takasi ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c NONE   (Japan)

Author keywords

5 fluorouracil; Alternating chemoradiotherapy; Head and neck cancer; Nedaplatin; Radiotherapy

Indexed keywords

FLUOROURACIL; GRANISETRON; NEDAPLATIN; ONDANSETRON; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447633234     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl138     Document Type: Article

References (41)

1. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Jr, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
2. Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: Results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 2005;23:1447-54.
3. Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005;23:3008-15.
4. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-6.
5. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-4.
6. Paolicchi A, Sotiropuolou M, Perego P, Daubeuf S, Visvikis A, Lorenzini E, et al. Gamma-glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. Eur J Cancer 2003;39:996-1003.
7. Melichar B, Kohout P, Bratova M, Solichova D, Kralickova P, Zadak Z. Intestinal permeability in patients with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol 2001;127:314-8.
8. Erdinc M, Erdinc L, Nergiz Y, Isik B. Potentiation of cisplatin-induced nephrotoxicity in rats by allopurinol. Exp Toxicol Pathol 2000;52: 329-34.
9. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, et al. Pharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23:243-6.
10. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, et al. Phase I study and pharmacological analysis of cis diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 1991;51:1472-7.
11. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 1992;19: 863-9.
12. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 1992; 19:871-7.
13. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004; 40:1000-6.
14. Ita M, Okafuji M, Fukuda K, Mitsuoka K, Hanakita T, Hayatsu Y. Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral Oncol 2003;39:144-9.
15. Hirabayashi K, Okada E. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer. Cancer 1993;71:2769-75.
16. Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 2004;91:1032-7.
17. Yoshioka T, Gamoh M, Shineha R, Ishibashi S, Shibata H, Suzuki T, et al. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med 1999;38:844-8.
18. Kato H, Fukuchi M, Manda R, Nakajima M, Miyazaki T, Sohda M, et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 2003; 23:3493-8.
19. Nemoto K, Matsushita H, Ogawa Y, Takeda K, Takahashi C, Britton KR, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 2003; 26:46-9.
20. Athanasiadis I, Taylor S 4th, Vokes EE, Pelzer HJ, Rademaker A, Mittal BB, et al. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. Cancer 1997; 79:1588-94.
21. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7.
22. Decker DA, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh JJ, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983;51:1353-5.
23. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17: 1339-48.
24. Takeda Y, Kasai H, Uchida N, Yoshida H, Maekawa R, Sugita K, et al. Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts. Anticancer Res 1999;19: 4059-64.
25. Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer 1998;34:1796-801.
26. Ariyoshi Y, Ota K, Wakui A. Phase I study of (glycolato-O,O′) diammineplatinum (II)(254-S). Proc Am Soc Clin Oncol 1988;7:59.
27. Fuwa N, Kodaira T, Kamata M, Matsumoto A, Furutani K, Tachibana H, et al. Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): Adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol 2002;25:565-9.
28. Fuwa N, Ito Y, Kodaira T, Matsumoto A, Kamata M, Furutani K, et al. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: Its usefulness and controversial points. Jpn J Clin Oncol 2001;31:589-95.
29. Fuwa N, Kano M, Toita T, Shikama N, Kodaira T, Matsumoto A, et al. Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: A preliminary report of phase II study. Radiother Oncol 2001;61:257-60.
30. International Union Against Cancer. TNM classification of malignant tumours, 5th edn. Sobin LH, Wittekind Ch, editors. New York: Wiley-Liss 1997.
31. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization 1979;14-27.
32. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practice design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
33. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J. Am. Stat. Assoc. 1958;53:475-81.
34. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
35. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
36. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-83.
37. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18:1458-64.
38. Staar S, Radar V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71.
39. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991;67:915-21.
40. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-9.
41. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.